News

2026/09/18 Global MASLD Burden Reaches 1.3 Billion People and Could Rise to 1.8 Billion by 2050, New GBD Study

Global MASLD Burden Reaches 1.3 Billion People and Could Rise to 1.8 Billion by 2050, New GBD Study Finds

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has become an increasingly important global health challenge. A new study published in The Lancet Gastroenterology & Hepatology estimates that approximately 1.3 billion people worldwide were living with MASLD in 2023, accounting for 16.1% of the global population, or roughly one in six people.
 
The study, conducted as part of the Global Burden of Disease (GBD) Study 2023, provides the most comprehensive assessment to date of the global, regional, and national burden of MASLD. Researchers analyzed data from 204 countries and territories between 1990 and 2023, examining MASLD prevalence and disability-adjusted life-years (DALYs) by age, sex, and level of development. The study also assessed the contribution of major modifiable risk factors and projected the future burden of MASLD through 2050.
 
The findings show a substantial increase in the number of people living with MASLD over the past three decades. The estimated number of cases increased from approximately 500 million in 1990 to 1.3 billion in 2023, representing a 142.7% increase. The age-standardized prevalence rate also increased by 28.6% during the same period. In 2023, approximately 3.6 million DALYs were attributable to MASLD globally. Despite more than doubling in absolute numbers since 1990, the age-standardized DALY rate remained relatively stable, suggesting that the growing number of cases has not yet translated into a proportional increase in severe health loss.
 
The burden varied substantially across regions. North Africa and the Middle East had the highest age-standardized prevalence rate, whereas the high-income Asia Pacific region had the lowest. Lower levels of healthcare access and quality were also associated with higher age-standardized DALY rates, highlighting potential challenges for health systems in managing the growing burden of MASLD and its complications.
 
The study further identified important opportunities for prevention. Among the modifiable risk factors examined, high fasting plasma glucose contributed the largest share of the age-standardized DALY rate associated with MASLD, followed by high body-mass index (BMI) and smoking. These findings highlight the close connection between MASLD and broader metabolic health, and suggest that prevention strategies addressing diabetes, obesity, and tobacco use may also help reduce the future burden of liver disease.
 
Looking ahead, the researchers project that approximately 1.8 billion people could be living with MASLD by 2050, representing a 42.0% increase from 2023. The projected rise is expected to be driven primarily by population growth, particularly in sub-Saharan Africa and North Africa and the Middle East, with additional contributions from changes in the underlying epidemiology.
 
The findings underscore that MASLD is not simply a liver disease, but an emerging global public health challenge closely linked to metabolic risk factors. As the number of people affected continues to grow, strengthening prevention, early detection, clinical management, and health-system capacity will be essential to reduce the long-term health impact of MASLD and its potential progression to advanced liver disease.
 
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00011-7/fulltext